1-20 of 184
Sort by
News

Magrolimab/Azacitidine Did Not Improve Outcomes in TP53-Mutated AML

Leah Lawrence
Published: 2025
Abstract
June 2025
View News titled, Magrolimab/Azacitidine Did Not Improve Outcomes in TP53-Mutated AML
News

Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML

Anna Azvolinsky, PhD
Published: 2025
Abstract
May 2025
View News titled, Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML
News

Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML

Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML
News

Final CAVEAT Results Further Support Venetoclax Plus Intensive Chemotherapy in Older Patients With AML

Leah Lawrence
Published: 2025
Abstract
April 2025
View News titled, Final CAVEAT Results Further Support Venetoclax Plus Intensive Chemotherapy in Older Patients With AML
News

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T, NCT04161885)

Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T, NCT04161885)
News

Obecabtagene Autoleucel Effective Treatment for Adults with B-ALL

Lara C. Pullen, PhD
Published: 2025
Abstract
March 2025
View News titled, Obecabtagene Autoleucel Effective Treatment for Adults with B-ALL
News

CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study

Katie Robinson
Published: 2025
Abstract
April 2025
View News titled, CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study
News

Predicting Response to Obe-Cel in Patients With R/R B-ALL

Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Predicting Response to Obe-Cel in Patients With R/R B-ALL
News

Combination of Venetoclax, Lower Intensity CPX-351 Shows Positive Results in Early-Stage AML Study

Anna Azvolinsky, PhD
Published: 2025
Abstract
February 2025
View News titled, Combination of Venetoclax, Lower Intensity CPX-351 Shows Positive Results in Early-Stage AML Study
News

New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML

Lara C. Pullen, PhD
Published: 2024
Abstract
December 2024
View News titled, New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML
News

Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose

Lara C. Pullen, PhD
Published: 2024
Abstract
December 2024
View News titled, Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose
News

Geriatric Assessment-Guided Conditioning Reduced Non-Relapse Mortality for Transplant in Myeloid Malignancies

Leah Lawrence
Published: 2024
Abstract
January 2025
View News titled, Geriatric Assessment-Guided Conditioning Reduced Non-Relapse Mortality for Transplant in Myeloid Malignancies
News

Addition of Induction Gilteritinib May Provide Some Benefit for Newly Diagnosed FLT3-Mutated AML

Leah Lawrence
Published: 2024
Abstract
January 2025
View News titled, Addition of Induction Gilteritinib May Provide Some Benefit for Newly Diagnosed FLT3-Mutated AML
News

Blinatumomab Added to Chemotherapy Is New Standard of Care in Newly Diagnosed Childhood SR B-ALL

Khylia Marshall
Published: 2024
Abstract
January 2025
View News titled, Blinatumomab Added to Chemotherapy Is New Standard of Care in Newly Diagnosed Childhood SR B-ALL
News

Socioeconomic Factors, Education Levels Affect Access to AlloHCT for AML

Lara C. Pullen, PhD
Published: 2024
Abstract
January 2025
View News titled, Socioeconomic Factors, Education Levels Affect Access to AlloHCT for AML
News

Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Respond Well to Asciminib, Dasatinib

Lara C. Pullen, PhD
Published: 2024
Abstract
December 2024
View News titled, Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Respond Well to Asciminib, Dasatinib
News

Venetoclax Effective for Bridging to Transplant in R/R AML, Study Suggests

Thomas R. Collins
Published: 2024
Abstract
Mid-November 2024
View News titled, Venetoclax Effective for Bridging to Transplant in R/R AML, Study Suggests
News

Genetics-Based Risk Model to Stratify Survival Outcomes of Patients With AML Treated With Venetoclax-Azacitidine

Anna Azvolinsky, PhD
Published: 2024
Abstract
November 2024
View News titled, Genetics-Based Risk Model to Stratify Survival Outcomes of Patients With AML Treated With Venetoclax-Azacitidine
News

Drawing First Blood: Will Menin Inhibitors Revolutionize the Treatment of AML?

Leah Lawrence
Published: 2024
Abstract
October 2024
View News titled, Drawing First Blood: Will Menin Inhibitors Revolutionize the Treatment of AML?
News

Study Examines Development of Paraparesis, Quadriparesis in Pediatric Patients With B-ALL Treated With CAR T-Cell Therapy

Anna Azvolinsky, PhD
Published: 2024
Abstract
September 2024
View News titled, Study Examines Development of Paraparesis, Quadriparesis in Pediatric Patients With B-ALL Treated With CAR T-Cell Therapy